BACKGROUND: Several risk loci for Alzheimer's disease (AD) have been identified during recent years in large-scale genome-wide association studies. However, little is known about the mechanisms by which these loci influence AD pathogenesis. OBJECTIVE: To investigate the individual and combined risk effects of the newly identified AD loci. METHODS: Association of 12 AD risk loci with AD and AD-related cerebrospinal fluid (CSF) biomarkers was assessed. Furthermore, a polygenic risk score combining the effect sizes of the top 22 risk loci in AD was calculated for each individual among the clinical and neuropathological cohorts. Effects of individual risk loci and polygenic risk scores were assessed in relation to CSF biomarker levels as well as neurofibrillary pathology and different biochemical measures related to AD pathogenesis obtained from the temporal cortex. RESULTS: Polygenic risk scores associated with CSF amyloid-β42 (Aβ42) levels in the clinical cohort, and with soluble Aβ42 levels and γ-secretase activity in the neuropathological cohort. The γ-secretase effect was independent of APOE. APOE-ε4 associated with CSF Aβ42 (p < 0.001) levels. For the other risk loci, no significant associations with AD risk or CSF biomarkers were detected after multiple testing correction. CONCLUSIONS: AD risk loci polygenically contribute to Aβ pathology in the CSF and temporal cortex, and this effect is potentially associated with increased γ-secretase activity.
BACKGROUND: Several risk loci for Alzheimer's disease (AD) have been identified during recent years in large-scale genome-wide association studies. However, little is known about the mechanisms by which these loci influence AD pathogenesis. OBJECTIVE: To investigate the individual and combined risk effects of the newly identified AD loci. METHODS: Association of 12 AD risk loci with AD and AD-related cerebrospinal fluid (CSF) biomarkers was assessed. Furthermore, a polygenic risk score combining the effect sizes of the top 22 risk loci in AD was calculated for each individual among the clinical and neuropathological cohorts. Effects of individual risk loci and polygenic risk scores were assessed in relation to CSF biomarker levels as well as neurofibrillary pathology and different biochemical measures related to AD pathogenesis obtained from the temporal cortex. RESULTS: Polygenic risk scores associated with CSF amyloid-β42 (Aβ42) levels in the clinical cohort, and with soluble Aβ42 levels and γ-secretase activity in the neuropathological cohort. The γ-secretase effect was independent of APOE. APOE-ε4 associated with CSF Aβ42 (p < 0.001) levels. For the other risk loci, no significant associations with AD risk or CSF biomarkers were detected after multiple testing correction. CONCLUSIONS:AD risk loci polygenically contribute to Aβ pathology in the CSF and temporal cortex, and this effect is potentially associated with increased γ-secretase activity.
Entities:
Keywords:
Alzheimer's disease; amyloid-β peptide; biomarker; cerebrospinal fluid; polygenic risk score; risk gene; tau protein
Authors: Yuetiva Deming; Zeran Li; Manav Kapoor; Oscar Harari; Jorge L Del-Aguila; Kathleen Black; David Carrell; Yefei Cai; Maria Victoria Fernandez; John Budde; Shengmei Ma; Benjamin Saef; Bill Howells; Kuan-Lin Huang; Sarah Bertelsen; Anne M Fagan; David M Holtzman; John C Morris; Sungeun Kim; Andrew J Saykin; Philip L De Jager; Marilyn Albert; Abhay Moghekar; Richard O'Brien; Matthias Riemenschneider; Ronald C Petersen; Kaj Blennow; Henrik Zetterberg; Lennart Minthon; Vivianna M Van Deerlin; Virginia Man-Yee Lee; Leslie M Shaw; John Q Trojanowski; Gerard Schellenberg; Jonathan L Haines; Richard Mayeux; Margaret A Pericak-Vance; Lindsay A Farrer; Elaine R Peskind; Ge Li; Antonio F Di Narzo; John S K Kauwe; Alison M Goate; Carlos Cruchaga Journal: Acta Neuropathol Date: 2017-02-28 Impact factor: 17.088
Authors: AmanPreet Badhwar; G Peggy McFall; Shraddha Sapkota; Sandra E Black; Howard Chertkow; Simon Duchesne; Mario Masellis; Liang Li; Roger A Dixon; Pierre Bellec Journal: Brain Date: 2020-05-01 Impact factor: 13.501
Authors: Burcu F Darst; Rebecca L Koscik; Annie M Racine; Jennifer M Oh; Rachel A Krause; Cynthia M Carlsson; Henrik Zetterberg; Kaj Blennow; Bradley T Christian; Barbara B Bendlin; Ozioma C Okonkwo; Kirk J Hogan; Bruce P Hermann; Mark A Sager; Sanjay Asthana; Sterling C Johnson; Corinne D Engelman Journal: J Alzheimers Dis Date: 2017 Impact factor: 4.472
Authors: Vincent Chouraki; Christiane Reitz; Fleur Maury; Joshua C Bis; Celine Bellenguez; Lei Yu; Johanna Jakobsdottir; Shubhabrata Mukherjee; Hieab H Adams; Seung Hoan Choi; Eric B Larson; Annette Fitzpatrick; Andre G Uitterlinden; Philip L de Jager; Albert Hofman; Vilmundur Gudnason; Badri Vardarajan; Carla Ibrahim-Verbaas; Sven J van der Lee; Oscar Lopez; Jean-François Dartigues; Claudine Berr; Philippe Amouyel; David A Bennett; Cornelia van Duijn; Anita L DeStefano; Lenore J Launer; M Arfan Ikram; Paul K Crane; Jean-Charles Lambert; Richard Mayeux; Sudha Seshadri Journal: J Alzheimers Dis Date: 2016-06-18 Impact factor: 4.472
Authors: Aamira J Huq; Brian Fulton-Howard; Moeen Riaz; Simon Laws; Robert Sebra; Joanne Ryan; Alan E Renton; Alison M Goate; Colin L Masters; Elsdon Storey; Raj C Shah; Anne Murray; John McNeil; Ingrid Winship; Paul A James; Paul Lacaze Journal: Alzheimers Dement (Amst) Date: 2021-08-05
Authors: Sultan Chaudhury; Tulsi Patel; Imelda S Barber; Tamar Guetta-Baranes; Keeley J Brookes; Sally Chappell; James Turton; Rita Guerreiro; Jose Bras; Dena Hernandez; Andrew Singleton; John Hardy; David Mann; Kevin Morgan Journal: Neurobiol Aging Date: 2017-10-10 Impact factor: 4.673